{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:53:59Z","timestamp":1794110039505,"version":"4.8.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01120-9","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T03:02:46Z","timestamp":1726196566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4001-9622","authenticated-orcid":false,"given":"Nisha S.","family":"Joseph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-6429","authenticated-orcid":false,"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-2338","authenticated-orcid":false,"given":"Vilas A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4816-1607","authenticated-orcid":false,"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8249-5988","authenticated-orcid":false,"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-8815","authenticated-orcid":false,"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"DiCamillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-9323","authenticated-orcid":false,"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"issue":"2","key":"1120_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2204925","journal-title":"N Engl J Med"},{"key":"1120_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02515","volume":"38","author":"N Joseph","year":"2020","unstructured":"Joseph N, Kaufman J, Dhodapkar M, Hofmeister C, Almaula D, Heffner L, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38:JCO.19.02515 https:\/\/doi.org\/10.1200\/JCO.19.02515","journal-title":"J Clin Oncol"},{"key":"1120_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679\u201386. https:\/\/doi.org\/10.1182\/blood-2010-02-268862","journal-title":"Blood"},{"key":"1120_CR4","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2022.40.16_suppl.8061","volume":"40","author":"RHC Parikh","year":"2022","unstructured":"Parikh RHC, Almaula D, Heffner LT, Gupta VA, Boise L, Kaufman JL, et al. Updated survival with extended follow-up on patients with newly diagnosed multiple myeloma treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach. J Clin Oncol. 2022;40:1806","journal-title":"J Clin Oncol"},{"key":"1120_CR5","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10:e825\u2013e37. https:\/\/doi.org\/10.1016\/S2352-3026(23)00217-X","journal-title":"Lancet Haematol"},{"key":"1120_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301\u201313. https:\/\/doi.org\/10.1056\/NEJMoa2312054","journal-title":"N Engl J Med"},{"key":"1120_CR7","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267","journal-title":"J Clin Oncol"},{"key":"1120_CR8","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"1120_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/jha2.129","volume":"2","author":"P Moreau","year":"2021","unstructured":"Moreau P, Hulin C, Zweegman S, Hashim M, Hu Y, Heeg B, et al. Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA\/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching. EJHaem. 2021;2:66\u201380. https:\/\/doi.org\/10.1002\/jha2.129","journal-title":"EJHaem"},{"key":"1120_CR10","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9:e810\u2013e21. https:\/\/doi.org\/10.1016\/S2352-3026(22)00263-0","journal-title":"Lancet Haematol"},{"key":"1120_CR11","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e890\u2013e901. https:\/\/doi.org\/10.1016\/S2352-3026(23)00236-3","journal-title":"Lancet Haematol"},{"key":"1120_CR12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41375-021-01431-x","volume":"36","author":"LB Leypoldt","year":"2022","unstructured":"Leypoldt LB, Besemer B, Asemissen AM, Hanel M, Blau IW, Gorner M, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia. 2022;36:885\u20138. https:\/\/doi.org\/10.1038\/s41375-021-01431-x","journal-title":"Leukemia"},{"key":"1120_CR13","doi-asserted-by":"publisher","unstructured":"Touzeau C, Perrot A, Hulin C, Manier S, Macro MD, Chretien ML, et al. Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma. Blood. 2024. https:\/\/doi.org\/10.1182\/blood.2023023597","DOI":"10.1182\/blood.2023023597"},{"key":"1120_CR14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/leu.2013.335","volume":"28","author":"AK Nooka","year":"2014","unstructured":"Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014;28:690\u20133. https:\/\/doi.org\/10.1038\/leu.2013.335","journal-title":"Leukemia"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01120-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T03:03:49Z","timestamp":1726196629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01120-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01120-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4138395\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nisha S. Joseph has served on advisory boards and reports consultancy for Janssen Oncology, Bristol-Myers Squibb; research funding from Janssen, Bristol-Myers Squibb, Takeda, AstraZeneca, GSK. Jonathan L. Kaufman reports consultancy for and research funding from Janssen, Takeda, Bristol-Myers Squibb, Celgene, AbbVie, Roche, Seattle Genetics, Amgen, Sutro Biopharma, Karyopharm, Celgene, and Pharmacyclics outside the submitted work. Craig C. Hofmeister has served on an advisory board for Celgene and reports being the principal investigator of company-sponsored trials for Janssen, Celgene, Bristol-Myers Squibb, and Takeda-Millennium outside the submitted work. Ajay K. Nooka has served on advisory boards for Amgen, Spectrum Pharmaceuticals, Takeda Pharmaceuticals, Celgene, Bristol-Myers Squibb, GlaxoSmithKline, Adaptive Technologies, and Janssen Pharmaceuticals and reports grants from Amgen Pharmaceuticals, Takeda Pharmaceuticals, Bristol-Myers Squibb, Janssen Pharmaceuticals, Celgene, and GSK during the conduct of the study; he also reports grants from Novartis, Roche, and KITE outside the submitted work. Madhav V. Dhodapkar reports personal fees from Amgen and Janssen outside the submitted work. Sagar Lonial reports consultancy for and research funding from Takeda, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Amgen, Merck, Celgene, and Janssen outside the submitted work. The other authors made no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All data was de-identified and compiled as per our institutional IRB-approved protocol. Per IRB52278, we received a waiver of consent from Emory University IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"159"}}